November 9, 2020
November 9, 2020 – BusinessWire – FLG Partner client, Angion Biomedica and Vifor Pharma have signed a license agreement for ANG-3777 in nephrology indications. Through this strategic partnership, Vifor Pharma acquires a worldwide license, excluding Greater China, to late-stage product ANG-3777. ANG-3777 is a first in class small-molecule hepatocyte growth factor (HGF) mimetic, addressing a significant unmet need for the treatment of delayed graft function (DGF) and cardiac surgery-associated acute kidney injury (CSA-AKI). Addressable patients with DGF is estimated to be about 15,000 and approximately 110,000 with CSA-AKI in the US/EU5 each year. Under the terms of the agreement, Angion will receive up to $80 million, which includes $30 million in upfront payments, $30 million in equity investment and $20 million clinical study milestone payments with further milestone payments and tiered royalties based on global sales. FLG partner Greg Curhan assisted.
“Vifor Pharma is one of the world leaders in the nephrology space and we are very excited to partner with them on the commercialization of ANG‑3777 for nephrology indications,” stated Dr. Jay Venkatesan, President and CEO of Angion. “This is a major milestone for the team at Angion who has worked for many years to develop ANG-3777 as a therapy for patients with acute kidney injuries. We look forward to phase-III data in DGF towards the end of 2021 and working with Vifor Pharma to potentially bring ANG-3777 to nephrology patients worldwide.”
Full press release is here.